Scholar Rock Holding Corporation
SRRKDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
PDUFA
Scholar Rock has a PDUFA decision date in September 2026 for a new treatment targeting SMA patients. The announcement indicates regulatory progress for the company's therapeutic candidate.
FDA approval for Isembyld (apitegromab-mstn) for SMA
SourceHow SRRK's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Apitegromab | Phase 3 | Spinal Muscular Atrophy | - | - |
SRK-015 | Phase 2 | Spinal Muscular Atrophy | - | - |
Frequently asked questions
What is in Scholar Rock Holding Corporation's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Scholar Rock Holding Corporation's (SRRK) pipeline across Phase 3, Phase 2. Its lead program is Apitegromab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Scholar Rock Holding Corporation's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Scholar Rock Holding Corporation (SRRK) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SRRK biotech catalysts?→
Add SRRK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Scholar Rock Holding Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.